PFS Genomics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$33.6M
PFS Genomics General Information
Description
Developer of breast cancer radiotherapy tests intended to identify which women with early-stage invasive breast cancer truly need radiation therapy. The company's tests indicate if the radiation therapy can benefit the patient, enabling doctors to personalize the treatment of breast cancer patients, improve outcomes and reduce unnecessary treatment.
Contact Information
Website
www.pfsgenomics.comCorporate Office
- Vancouver, British Columbia
- Canada
Corporate Office
- Vancouver, British Columbia
- Canada
PFS Genomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 03-May-2021 | $33.6M | Completed | Generating Revenue | ||
| 1. Early Stage VC | Completed | Startup |
PFS Genomics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PFS Genomics Patents
PFS Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022228444-A1 | Methods and genomic classifiers for prognosis of breast cancer and identifying subjects not likely to benefit from radiotherapy | Pending | 01-Mar-2021 | ||
| CA-3210617-A1 | Methods and genomic classifiers for prognosis of breast cancer and identifying subjects not likely to benefit from radiotherapy | Pending | 01-Mar-2021 | ||
| EP-4301867-A1 | Methods and genomic classifiers for prognosis of breast cancer and identifying subjects not likely to benefit from radiotherapy | Inactive | 01-Mar-2021 | ||
| US-20240145032-A1 | Methods and genomic classifiers for prognosis of breast cancer and identifying subjects not likely to benefit from radiotherapy | Pending | 01-Mar-2021 | ||
| JP-2022512152-A | Transcriptome profiling for breast cancer prognosis | Pending | 08-Dec-2018 | G01N33/57415 |
PFS Genomics Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Albany Capital (Australia) | Venture Capital | Minority | ||
| Innovation Partnerships | Venture Capital | Minority |
PFS Genomics FAQs
-
When was PFS Genomics founded?
PFS Genomics was founded in 2015.
-
Where is PFS Genomics headquartered?
PFS Genomics is headquartered in Vancouver, Canada.
-
What industry is PFS Genomics in?
PFS Genomics’s primary industry is Diagnostic Equipment.
-
Is PFS Genomics a private or public company?
PFS Genomics is a Private company.
-
What is the current valuation of PFS Genomics?
The current valuation of PFS Genomics is .
-
What is PFS Genomics’s current revenue?
The current revenue for PFS Genomics is .
-
Who are PFS Genomics’s investors?
Albany Capital (Australia) and Innovation Partnerships have invested in PFS Genomics.
-
When was PFS Genomics acquired?
PFS Genomics was acquired on 03-May-2021.
-
Who acquired PFS Genomics?
PFS Genomics was acquired by Exact Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
